#United States #Washington, D.C. #Vanda Pharmaceuticals #IndyCar #NEREUS™

NEREUS™ No. 47 IndyCar to Compete in Historic Freedom 250 Grand Prix

Vanda Pharmaceuticals Inc. has officially announced that its NEREUS™ branded No. 47 IndyCar, driven by rising star Mick Schumacher, will take part in the first-ever Freedom 250 Grand Prix, set to take place on August 22-23, 2026, in Washington, D.C. This major event marks a significant milestone, as it is not only the inaugural race of the NTT INDYCAR SERIES on the iconic National Mall but also celebrates America's 250th anniversary.

A Historic Racing Circuit

The Freedom 250 Grand Prix features a uniquely designed 1.7-mile street circuit that includes seven challenging turns, weaving its way past some of the most recognizable landmarks in the nation. This distinguished course will be framed by the majestic Washington Monument and the U.S. Capitol, creating a breathtaking backdrop for participants and fans alike.

The excitement begins on Saturday with practice and qualifying rounds, culminating in the thrilling 147-lap race on Sunday afternoon. The race itself is set to cover approximately 250 miles and will be broadcast live on FOX, attracting a vast audience eager to witness the high-speed showdown.

Sponsorship by NEREUS™

NEREUS™, a groundbreaking prescription medication approved by the FDA for preventing motion-induced vomiting, proudly sponsors the No. 47 Honda. This relationship between Vanda Pharmaceuticals and Rahal Letterman Lanigan Racing is symbolic of their shared commitment to performance under pressure. Mihael H. Polymeropoulos, M.D., President and CEO of Vanda, emphasized the alignment of NEREUS™’s mission with the demands of professional racing: "Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions."

With this event being a homecoming for Vanda, based in Washington, there’s a palpable excitement surrounding the race. Fans will have the opportunity to support their local team and witness an exceptional display of skill and speed.

About NEREUS™ and Vanda Pharmaceuticals

NEREUS™ (tradipitant) is the first new product in the U.S. to receive approval specifically targeting motion sickness in 47 years, demonstrating Vanda Pharmaceuticals' dedication to addressing significant healthcare needs. Apart from providing innovative treatments, Vanda aims to improve the quality of life for its patients, making its participation in such high-profile events even more meaningful.

Founded by Bobby Rahal, David Letterman, and Mike Lanigan, Rahal Letterman Lanigan Racing has established itself as a formidable presence in the NTT INDYCAR SERIES. This collaboration not only reflects their excellence in racing but also showcases their commitment to promoting brands that prioritize performance and reliability.

As racing enthusiasts gather in Washington, D.C. this August for the Freedom 250, all eyes will be on Schumacher and the NEREUS™ No. 47 IndyCar as they strive to make history in an exhilarating race showcasing American culture and spirit. Racing fans can subscribe to updates and follow the trials and feats of their favorite driver and team throughout the event weekend, looking forward to a remarkable celebration of speed and skill.

This race isn’t just about motorsports; it's an embodiment of passion, partnership, and the pursuit of excellence. Set against the historic landmarks of the nation’s capital, the Freedom 250 Grand Prix promises to be an unforgettable experience for participants and onlookers alike.